About
Dr. Reddy's Laboratories Ltd. is a leading Indian multinational pharmaceutical company based in Hyderabad, with a U.S. headquarters in East Brunswick, New Jersey. Founded in 1984 by Dr. Kallam Anji Reddy, the company aims to provide affordable and innovative medicines worldwide. It has a rich history, starting as a supplier of active pharmaceutical ingredients (APIs) and expanding into regulated markets in the 1990s. Notable achievements include launching the first biosimilar monoclonal antibody, Reditux, in 2007 and establishing a strong presence in over 66 countries. The company manufactures more than 190 medications and 60 APIs across three main segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Its therapeutic areas include gastroenterology, oncology, cardiovascular health, and more. Dr. Reddy's is also expanding into digital healthcare and global consumer health, emphasizing patient-centric initiatives through its foundation. With around 25,000 employees and revenues between USD 2.83-3.8 billion, Dr. Reddy's is committed to improving health outcomes for over 800 million patients globally.